Prime Medicine, Bristol Myers Squibb
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
4don MSN
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
15h
To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback